Katherine K. Matthay
Paediatric oncologist whose trials established transplant and 13-cis-retinoic acid for high-risk neuroblastoma.
Overview
Katherine Matthay is Professor Emerita of Pediatrics at UCSF, within the UCSF Helen Diller Family Comprehensive Cancer Center, and a neuroblastoma investigator with the Children's Oncology Group (COG). A paediatric oncologist and long-time chair of COG neuroblastoma studies, she led the CCG-3891 trial establishing myeloablative therapy and 13-cis-retinoic acid in high-risk neuroblastoma and pioneered 131I-MIBG therapy for relapsed disease. Her papers report the Children's Cancer Group trial of intensive chemotherapy, radiotherapy, autologous bone marrow transplantation and 13-cis-retinoic acid, and the long-term results of that randomised trial. Her work links iobenguane I-131 and radioligand therapy to paediatric neuroblastoma.
Similar pages
not linked directly; found by shared links- TrialCOG ANBL1531
Shares 131I-MIBG (iobenguane I-131) therapy, Neuroblastoma (paediatric), Iodine-131.
- TermMIBG Curie and SIOPEN scores
Shares 131I-MIBG (iobenguane I-131) therapy, Neuroblastoma (paediatric), Iodine-131.
- CompanyY-mAbs Therapeutics
Shares Neuroblastoma (paediatric), Iodine-131.
- PersonEmily K. Bergsland
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Radioligand therapy (beta emitters).
- PersonRahul Aggarwal
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Radioligand therapy (beta emitters).
- Key paperEfficacy and safety of high-specific-activity 131I-MIBG therapy in advanced pheochromocytoma or paraganglioma
- PersonNeeta Pandit-Taskar
Shares Neuroblastoma (paediatric), Iodine-131.
- InstitutionSahlgrenska University Hospital / Sahlgrenska Center for Cancer Research
Shares Neuroblastoma (paediatric), Radioligand therapy (beta emitters).